Health Canada Approves Biodexa's Serenta Phase 3 Expansion for FAP, Boosting Enrollment
BDRX is trading near its 52-week low of $2.45 (12% above the low) on elevated volume (5.0× avg).
Summary
Biodexa Pharmaceuticals received Health Canada approval to expand its Serenta registrational Phase 3 trial for Familial Adenomatous Polyposis (FAP) into Canada, adding 3-4 new clinical centers. This expansion is expected to accelerate patient enrollment, which has already seen an uptick, with 73 of 168 target patients now enrolled. For a micro-cap biotech, progress in a pivotal Phase 3 trial for a condition with no approved treatments is highly material, de-risking the lead asset and potentially speeding up market access. This positive clinical development follows recent corporate governance news regarding a postponed AGM and a proposed reverse stock split.
At the time of this announcement, BDRX was trading at $2.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $2.45 to $66.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.